Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of “Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a consensus rating of “Buy” from the eight research firms that are presently covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have covered the stock in the last year is $50.5714.

Several brokerages have recently commented on ARCT. Leerink Partners decreased their price target on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating on the stock in a research note on Friday, August 22nd. HC Wainwright began coverage on Arcturus Therapeutics in a research report on Thursday, September 4th. They set a “buy” rating and a $60.00 target price on the stock. Scotiabank restated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Wells Fargo & Company decreased their price objective on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 12th. Finally, Wall Street Zen raised shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th.

Arcturus Therapeutics Stock Up 6.8%

NASDAQ:ARCT opened at $21.88 on Friday. The firm’s fifty day simple moving average is $17.04 and its 200-day simple moving average is $13.88. The stock has a market cap of $594.15 million, a PE ratio of -9.81 and a beta of 2.39. Arcturus Therapeutics has a fifty-two week low of $8.04 and a fifty-two week high of $25.42.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.77. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. The firm had revenue of $28.30 million for the quarter, compared to the consensus estimate of $17.64 million. Equities analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. lifted its stake in Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 738 shares in the last quarter. Byrne Asset Management LLC raised its holdings in shares of Arcturus Therapeutics by 89.8% in the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 1,365 shares during the last quarter. US Bancorp DE lifted its position in shares of Arcturus Therapeutics by 218.9% in the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 2,329 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 2,586 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Arcturus Therapeutics by 3,482.9% during the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company’s stock valued at $550,000 after acquiring an additional 5,085 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.